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Despite diagnostic advances, breast cancer remains the most prevalent cancer among women in the United States. The
armamentarium of treatment options for metastatic disease is limited and mostly ineﬀective with regards to eradicating cancer.
However, there have been novel ﬁndings in the recent literature that substantiate the function of the microenvironment in
breast cancer progression and the support of metastasis to tertiary sites such as bone marrow. The uncovered signiﬁcance of
the microenvironment in the pathophysiology of breast cancer metastasis has served to challenge previously widespread theories
and introduce new perspectives for the future research to eradicate breast cancer. This paper delineates the current understanding
of the molecular mechanisms involved in the interactions between breast cancer cells and the microenvironment in progression,
metastasis, and dormancy. The information, in addition to other mechanisms described in bone marrow, is discussed in the paper.
1.Introduction
The ability to invade and metastasize allows cancer cells
to leave sites of primary tumor formation and recolonize
in new tissues. This oﬀers immediate metastasis to distant
sites as well as the establishment of dormancy. Metastases
are responsible for approximately 90% of human cancer
deaths [1]. The previously established theory on metasta-
sis described the phenomenon as a process alike to the
Darwinian evolution [2]. In that perspective, cancer cells
undergo a process of natural selection which favors rare cells
within a tumor capable of invading and growing at sites
of metastasis. The natural selection was believed to involve
the development of stable genetic alterations which proﬀer
the potential for successful metastasis. However, advances in
technology, especially the development of high-throughput
microarray expression proﬁling and in vivo imaging, have
served to challenge this perspective of cancer metastasis [2].
Research suggests that metastatic ability is gained at earlier
stages of tumor expansion than predicted by the previous
model, and that this ability is acquired through transient
changes in gene expression. A new tumor microenvironment
invasion model reconciles the Darwinian perspective with
recent discoveries. The tumor microenvironment consists
of surrounding stroma, which is composed of extracellular
matrix and various cell types including endothelial cells,
ﬁbroblasts, and inﬁltrative leukocytes.
The microenvironment, in addition to providing a scaf-
fold for the organ, has been found to play a signiﬁcant role
in breast cell function through paracrine, mechanical, and
hormonal interactions [3]. In the tumor microenvironment
invasion model, stable genetic changes in primary tumor
cells induce the microenvironment to initiate transient
changes in gene expression which promote invasiveness and
metastasis. Hence, the tumor microenvironment invasion
model predicts that selected mutations within primary can-
cer cells drive the microenvironment to induce transient and
epigenetic changes required of metastasis [2, 4]. This model2 International Journal of Breast Cancer
is supported by in vivo imaging of mammary tumors, which
demonstrates the following regarding motile tumor cells:
theyrepresentonlyasmallpercentageoftumorcells,theyare
distributed throughout the tumor, and they are found most
commonly localized to precise areas within the tumor [5].
Furthermore, genes associated with metastasis are expressed
early and are found in tumor cells throughout the tumor
[2]. Also in support of the model is the observation that
micrometastases are commonly genetically heterogeneous,
indicatingthattheinvasivenessandmigrationarenotlimited
to stable gene alterations.
Dormant cancer cells can remain quiescent for >10
years. Cancer can resurge and metastasize to tertiary organs.
However, similar dormancy can occur in other organs.
This paper will discuss on the bone marrow biology and
describe how cancer cells could take advantage of the bone
marrow microenvironment to adapt a dormant phenotype.
Dormancy is deﬁned as a state of fully transformed cells
with nontumorigenic property that resists anticancer agents.
Clinical dormancy has been deﬁned as the time (5–25yrs)
between removing the primary tumor and relapse [6]. We
expand this deﬁnition by proposing that dormant breast
cancer cells exist in bone marrow and other organs long
before clinical detection of the tumor [7].
We focus on bone marrow mostly due to its implication
as the source of tumor-initiating cells in a large number
of breast cancer resurgence [8, 9]. Also, prognosis is worse
when breast cancer cells micrometastasize to the bone
marrow[10].Anunderstandingofthemechanismsbywhich
the bone marrow microenvironment facilitates a dormant
phenotype of breast cancer cells is signiﬁcant for strategies
to target dormant breast cancer cells with minimum toxicity.
Bone marrow stromal cells, which are located close to the
endosteum, support breast cancer cell quiescence as well as
resurgence [11–15]. Quiescence is partly explained by the
production of cytokines from stroma and gap junctional
intercellular communication between the cancer cells and
stroma [13, 16, 17]. Gap junction facilitates the passage of
microRNA (miRNA) between the cancer cells and stroma
[16]. Among these miRNAs are those that target CXCL12,
which pass from stroma to breast cancer cells [16, 17].
Although the idea of crosstalk between the tumor and
the microenvironment to promote growth and metastasis
is now generally accepted in the ﬁeld of cancer biology,
the mechanisms underlying the interactions has not been
well established. For example, in the primary site, the
quantities and components of the microenvironment vary
among tumors [18]. Though tumors require stroma for
maintenance and growth, the malignant potential of a
tumor does not correlate with the amount of surrounding
stroma; both highly and less malignant cancer cells can
have abundant or scarce surrounding stroma [18]. Rather,
the microenvironmental eﬀects on tumor progression are
attributable to complex and dynamic epigenetic and phe-
notypic alterations. In addition to contributing to cancer
progression and metastasis, the microenvironment may also
play a pivotal role in protecting cancer cells from immune
surveillance and response. In this paper, we delineate the
current understanding of the microenvironemental involve-
ment in breast cancer progression, metastasis, and dormancy
in the mammary gland and then extrapolate the results to
dormancy in bone marrow.
2. Composition of the Microenvironment
Stromal-epithelial interactions have been implicated in
breast cancer progression [19, 20]. The composition of
the tumor stroma is diﬀerent from bone marrow stroma.
The whole bone marrow-supporting stroma are mostly
ﬁbroblasts, in other organs, the tumor stroma consists of
a heterogeneous population of cells, including pericytes,
tumor-associated macrophages, epithelial cells, endothe-
lial cells, ﬁbroblasts, myeloid-derived suppressor cells, and
adipocytes [21, 22]. Although each component might serve
a unique role in facilitating the growth of breast cancer at the
primary site, the stromal components are likely to interact
to support and protect the tumor. Interestingly, these same
cellular elements can be located at sites of distant metastasis,
where they serve to provide a supportive niche. Reciprocal
interactions between breast cancer cells and tumor stroma
at the primary site govern the behavior of cancer [23]. This
is explained by the report showing the secretion of soluble
factors from the cancer cells to activate the surrounding
stromal cells. Consequently, the stromal cells respond to
promote invasiveness of the breast cancer cells [24].
Tumor-associated macrophages constitute a major im-
mune cell population within the tumor microenvironment
and play an important role in chronic inﬂammation dur-
ing cancer progression [25]. Within the tumor-associated
macrophage population, there is a high level of plasticity
in terms of function [25, 26]. Primarily, the macrophages
stimulate the formation of new blood vessels in the tumor
bed via the production of vascular endothelial growth factor
[27]. In addition, the macrophage can also induce a state
of local immunosuppression, which can provide the tumor
withanadvantagetosurvivewithintheimmunesystem[25].
The role of macrophages is complex since these cells can also
promote the invasiveness of cancer via matrix remodeling
through the secretion of matrix metalloproteases MMP7 and
MMP9 [28]. Remodeling of the tumor stroma can also occur
through the production of CCL18 from tumor-associated
macrophages, which accelerates the invasive properties of
breast cancer [29].
The role of adipocytes in the primary tumor microenvi-
ronment has been studied recently in an eﬀort to determine
the eﬀects of obesity on cancer progression. Coculture of
adipocytes with breast cancer cells resulted in adipocyte acti-
vation and secretion of MMP11, as well as proinﬂammatory
cytokines IL-6 and IL-1β [24]. The increased production
of IL-6 from cancer-associated adipocytes promotes breast
cancer cell invasion [24]. Since obesity results in poor
prognosis of breast cancer [30] and adipose tissues are a
source of mesenchymal stem cells [31], studies on adipose
cells are relevant to the well-established interaction between
mesenchymal stem cells and breast cancer cells [32]. Mes-
enchymal stem cells, through the production of interleukin-
6, can enhance breast tumor growth [23].International Journal of Breast Cancer 3
Additional role of mesenchymal stem cells are included
inthissection.Theroleofﬁbroblastswithinthebreasttumor
microenvironment as cellular support for cancer cells is not
mutuallyexclusiveofmesenchymalstemcells.Solublefactors
from tumors are thought to diﬀerentiate mesenchymal
stem cells into myoﬁbroblast, which produce stromal cell-
derived factor-1 (SDF-1) to accelerate breast cancer growth
[33]. The mechanisms underlying this interaction have
been determined to be hepatoma-derived growth factor and
cyclophilin B from the tumor-conditioned media [34]. In
addition, carcinoma-associated ﬁbroblasts can alter the local
T-cell balance by polarizing towards a Th2-type response,
and this resulted in the loss of the antitumor Th1 eﬀects
[35]. This immune switch is not only limited to the diﬀer-
entiated mesenchymal stem cells. Studies with bone marrow
mesenchymal stem cells showed similar ﬁndings, in addition
to increases in regulatory T cells and reduced production of
granzyme B to induce cytotoxicity [36].
The myeloid-derived suppressor cells can also protect
the tumors from the immune system [37]. Myeloid sup-
pressor cells are a heterogeneous collection of immune cells
with immune-inhibitory properties [38]. Their numbers are
increased in the circulation of patients with breast cancer
as compared to healthy controls [39]. Although the studies
on myeloid-derived suppressor cells in breast cancer are
relatively limited, this area is a rapidly expanding area of can-
cer research. Recent ﬁndings demonstrate that the myeloid
suppressor cells are capable of interfering with the activation
of antitumor T-cell responses. Interestingly, interluekin-12,
with antitumor activity [40], has been shown to decrease the
number of myeloid-derived suppressor cells in the tumor
microenvironment [38], underscoring another mechanism
by which cells within the tumor microenvironment can
protect the cancer cells from the immune response.
Overall, this section provides an overview of the tumor
microenvironment at the primary site, with a diverse group
of cells that promote and protect tumors. The majority of
cells, however, appear to play key roles in breast cancer
growth at the primary sites. The bidirectional crosstalk
between breast cancer cells and microenvironmental com-
ponents cannot be overlooked, since cellular interactions in
vivo have a strong inﬂuence on the biological behavior of
cancer cells. The signiﬁcance of these ﬁndings points to an
important role for stromal-epithelial interactions in overall
breast cancer progression and metastasis. A recent review
paperdescribesthatashiftinthemicroenvironmentcanlead
to the tumor and how this information can be explored for
clinical intervention [20].
3. MechanicalInteractions
Although the interactions between tumor cells and stroma
through cytokines and other soluble factors has received
signiﬁcant attention in the literature, the less familiar topic
of mechanical interactions is also important to cancer
progression and metastasis. Cells within tissue are under
constant physical forces from neighboring cells and sur-
rounding extracellular matrix (ECM), and these forces can
be in the form of shear stress, compression, or tension.
Theseforcesfromthemicroenvironmentcanservetoinitiate
mechanical signaling pathways after being perceived by
mechanically responsive sensors present throughout the cell
[18]. This signaling can subsequently induce changes at
the molecular levels which promote cell survival, division,
and motility. For example, an important family of mechan-
otransducers is the integrins, plasma membrane proteins
which interact externally with ECM and internally with
components of the cytoskeleton [18]. Integrins can undergo
force-dependent activation resulting in the formation of
focal adhesions, which can serve to induce growth and
migration [41]. During the development of breast cancer,
tension homeostasis is signiﬁcantly perturbed [18]. There
are ampliﬁed compression forces secondary to pressure
from the progressively enlarging mass, matrix tightening
from desmoplastic changes, and elevated interstitial pres-
sure from leaky vasculature and compromised lymphatic
drainage [18]. This state of abnormal force leads to the
disruption of cell-cell junctions and polarity, and these
changes collectively promote anchorage-independent sur-
vival and invasion. Also, the compression stress can lead
to tumor angiogenesis directly through increasing VEGF-
A expression or indirectly by generating hypoxic conditions
through disrupting existing vasculature around the tumor,
which also ultimately leads to increased VEGF-A expression
[18].Furthermore,exceedingcompressionforcesigniﬁcantly
reduces surrounding interstitial space, which allows for
abnormal accumulation of ﬂuid from leaky vasculature
and blocked lymphatic drainage. This ﬂuid tends to con-
tain concentrations of cytokines and growth factors much
greater than physiologic levels, promoting aggressive tumor
expansion and migration. In addition, the overwhelming
interstitial pressure can also serve to obstruct access of
chemotherapeutic medications to the tumor. In summary,
the mechanical inﬂuences of the microenvironment are
extremely important to carcinogenesis and metastasis, and
hence this topic warrants further investigation.
4. Epithelial-to-Mesenchymal
Transition (EMT)
EMT is a complex phenomenon that is believed to play a role
in dormancy and metastasis. EMT is a normal physiologic
process during embryogenesis, wound healing and repair,
and tissue remodeling [42]. EMT is characterized by the
loss of epithelial polarity and the subsequent development
of a ﬁbroblast-like phenotype (Figure 1)[ 43]. The precise
mechanisms of EMT in breast cancer remains uncertain, but
it is believed to involve diverse changes at the genetic and
molecular levels. Phenotypically, EMT involves the loss of
epithelial cell markers such as E-cadherin, γ-catenin, zonula
occludens-1 (Zo-1), and the acquisition of mesenchymal
markers, such as vimentin, ﬁbronectin, and N-cadherin
[43]. The role of N-cadherin in promoting invasion, and
migration of cancer cell has been established [44]. Moreover,
the upregulation of EMT markers is correlated with poor
prognosis [44]. An examination of the cell qualities of4 International Journal of Breast Cancer
Figure 1: The epithelial-to-mesenchymal transition (EMT) is a physiological process by which an epithelial cell loses polarity and assumes a
mesenchymal phenotype. While EMT can occur naturally in gastrulation and wound repair, it is involved as a route of metastasis in cancer.
Through molecular changes, such as the loss of E-cadherin, the epithelial cell undergoes remodeling and loosens its attachments from the
basement membrane and adjoining cells to enter the vasculature. Once mobile, the malignant cells can take up residence at secondary sites,
reverting to an epithelial cell type or remaining dormant.
epithelial and mesenchymal cells demonstrates how EMT
promotes cancer metastasis. Epithelial cells are organized
tightly together to form a continuous layer above a basement
membrane, while mesenchymal cells are loosely anchored
and have the capability of becoming motile [45].
The microenvironment can trigger EMT through induc-
tion via upregulation of speciﬁc cytokines and growth
factors. TGF-β is known to be a potent inducer of
EMT, particularly during the early stages of carcinogenesis
[43]. Also, phorbol myristate acetate (PMA) can initiate
EMT through the activation of protein kinase C [46].
Furthermore, the microenvironment can inﬂuence EMT
through facilitating inﬂammation and accompanying leuko-
cyte migration. Inﬂammation-associated EMT involves epi-
genetic changes induced by the increased expression of NF-
κβ, Src, microRNAs, and IL-6 [3]. The mechanism through
which CD8+ T cells can induce EMT involves the induction
of CD44+/CD24− stem cell-like phenotype in breast cancer
cells,whichpromotesinvasivenessandmetastasis,alongwith
resistance to chemotherapy [3].
EMT is a particularly important area of‘microenviron-
ment-breast cancer crosstalk because it is a process that
can be potentially inhibited by therapeutic intervention.
Severalagentshaveshownpromisewithregardstoinhibition
of cancer progression associated with EMT. For example,
Withaferin-A, a biologically active inhibitor of vimentin, has
beenfoundtosuppressthemesenchymalphenotypethrough
the induction of apoptosis, while preventing angiogenesis
[47]. Also, Klf4, a well-known activator of E-cadherin, has
also been found to inhibit EMT and associated invasive
potential of transformed BCCs [43]. Inhibitors of the phos-
phatidylinositol 3-kinase (PI3K)/Akt/mTOR signaling, such
as phosphatidylinositol ether lipid analogs and rapamycin,
have been also found eﬀective in suppressing EMT [48].
Hence, these preliminary ﬁndings demonstrate the promis-
ing therapeutic potential of EMT modulators.
5. Dormancy
A signiﬁcant challenge of breast cancer treatment is the
transition of cancer cells to a dormant phenotype. The
literature supports that breast cancer relapses from bone
marrow years after remission, suggesting a preferential niche
inthebonemarrowmicroenvironmentforcirculatingtumor
cells [49]. Dormant cells are arrested at the G1 phase of cell
cycling. Quiescence proﬀers cancer cells with survival advan-
tage through resistance to chemotherapeutic agents, which
are designed to target proliferating cells [49]. Experimental
evidence suggests that dormant cancer cells exist in the bone
marrowneartheendosteum, wheretheyformgapjunctional
intercellular communication (GJIC) with hematopoietic-
supporting cells and stroma (Figure 2)[ 50]. Connexin 43
(Cx43) is involved in the formation of GJIC between breast
cancer cells and stroma [16]. An important factor of the
breast cancer cell-stroma crosstalk in the bone marrow
is CXCL12, a chemokine that interacts with CXCR4 and
CXCR7 [31]. CXCL12 is normally constitutively generated



















Figure 2: Stromal cells in the endosteal region of the bone marrow produce the chemokine, CXCL12, a known regulator in hematopoiesis.
Through an interaction between CXCL12 and CXCR4 (a receptor on the BCC), malignant cells are drawn from circulation to the stromal
niche. There, BCCs may form gap junctions with osteoblasts, which facilitates the intercellular transfer of small molecules such as miRNAs.
Experimental evidence demonstrates that micro-RNAs can traverse gap junctions and induce dormancy of BCCs.
cells contact stroma [17]. A decline in CXCL12 production
correlates with decreased breast cancer cell proliferation
[17]. A recent study identiﬁed certain microRNAs (miRNAs)
which cross GJICs between breast cancer cells and stroma
and speciﬁcally reduce CXCL12 levels [16]. In this study,
4 miRNAs were found to traverse GJICs and transition
BCCs to the G0 p h a s eo ft h ec e l lc y c l e[ 16]. These novel
ﬁndings suggest that microRNAs may play an integral role in
breast cancer dormancy in the bone marrow. Furthermore,
these data oﬀer signiﬁcant promise for developing treatment
options targeting dormant cancer cells. Currently, there is an
ongoing phase I clinical trial using siRNA to treat patients
with solid cancers; hence, targeting miRNAs may also be a
plausible treatment strategy in the near future [51].
Theinteractionbetweenmesenchymalstemcells(MSCs)
and BCCs in the bone marrow microenvironment is also
implicatedindormancy.IthasbeenfoundthatBCCsinteract
with MSCs through CXCL12-CXCR4 upon traversing blood
vessels in the bone marrow [49]. The mechanism through
which MSCs oﬀer protection to BCCs is hypothesized to
involve the immunosuppressive properties of MSCs [42].
MSCs have been found to induce the production of regula-
tory T cells (Tregs) when cocultured with BCCs, which allows
BCCs to evade immune response [52]. This concept of MSCs
preventing the eradication of cancer cells from physiologic
antitumorimmuneresponsesistermedoncoprotection[42].
The involvement of MSCs in breast cancer and other cancers
is rapidly expanding area of basic science research, which is
bound to lead to promising discoveries. The development of
therapies aimed at eliminating MSC-related oncoprotection
will be challenging, given the ubiquitous existence of MSCs
and their relevance to many important biological functions.
However, if further research uncovers speciﬁc distinctions
in MSCs involved in oncoprotection, compared to normal
MSCs, then the potential for therapy will certainly be more
promising.
6. Conclusion
Studies on the microenvironment of breast cancer are
rapidly growing. Novel ﬁndings in the recent literature
demonstrate the signiﬁcance of the microenvironment in the
progression, metastasis, and dormancy of breast cancer. The
objective for scientists, going forward, is transforming the
data gained from basic science research into eﬀective ther-
apeutic options. However, the precise mechanisms through
which the microenvironment induces molecular alterations
in cancer cells remain yet to be elucidated. Also, the
parallels of pathologic microenvironmental interactions and
physiologic roles pose signiﬁcant challenges to developing
treatment strategies free of adverse side eﬀects. Therefore,
further investigations aimed at deciphering the intricacies
of the microenvironment need to be performed to optimize
therapeutic development.
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